Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- Gene Therapy Access & RWE GuidanceEpisode 84 — 15 August 2026Examining CMS Part D gene therapy coverage, FDA RWE guidance, NICE digital health HTA, and EU Critical Medicines Act impact on HTA timelines.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- HCA Warning, Leqembi, Insulin, ICEREpisode 83 — 13 August 2026US hospital chain HCA's profit warning signals systemic access challenges; subQ Leqembi approval reshapes Alzheimer's HEOR; FTC insulin settlement impacts PBMs; ICER expands scientific advice scope.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
- Profit Warnings & Insulin PricingEpisode 82 — 12 August 2026HCA's profit warning signals US hospital system strain; subcutaneous Leqembi approval reshapes Alzheimer's evidence strategy; FTC insulin settlement impacts pharmacy benefit managers; ICER expands scientific advice capacity.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HCA Warning, Leqembi, FTC, ICEREpisode 81 — 11 August 2026HCA profit warning signals US healthcare access pressures; subQ Leqembi approval changes Alzheimer's HEOR; FTC insulin settlement sets pricing precedent; ICER expands scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Methodology Shifts & Digital Health IntegrationEpisode 77 — 05 August 2026Examining evolving HTA methodologies for complex therapies, IRA's influence on RWE strategies, patient-centric outcomes in rare diseases, and digital health integration challenges.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- System Stress & Evidence ShiftsEpisode 76 — 04 August 2026Analyzing systemic healthcare stressors, novel formulation evidence requirements, insulin pricing precedents, and evolving evidence assessment frameworks.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- US Access Signals & HEOR ShiftsEpisode 75 — 03 August 2026Examining US healthcare system pressures, novel formulation approvals, PBM transparency, and evolving evidence generation strategies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- Market Access CrosscurrentsEpisode 74 — 01 August 2026Examining HCA's profit warning signals, subcutaneous Leqembi's HEOR path, FTC insulin pricing impact, and ICER's expanded scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HTA Alignment & Gene Therapy ValueEpisode 73 — 29 July 2026Examining CMS Part D implementation challenges, ICER's novel Alzheimer's endpoints, EMA's adaptive pathway expansion, and FDA's gene therapy breakthrough updates.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HCA Profit Warning & Insulin Pricing ShiftsEpisode 72 — 28 July 2026HCA's uninsured surge signals systemic access challenges; subQ Leqembi reshapes Alzheimer's evidence needs; FTC insulin settlement alters PBM dynamics; ICER's Evidence First program redefines early engagement.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.